Trevor Allred
Stock Analyst at Oppenheimer
(4.90)
# 271
Out of 4,988 analysts
44
Total ratings
87.1%
Success rate
85.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $150.56 | +39.48% | 9 | Aug 5, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $66.61 | - | 10 | May 11, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $96.81 | - | 7 | May 11, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $27 → $14 | $17.02 | -19.68% | 2 | Mar 5, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $21.14 | +65.56% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $250 → $275 | $283.49 | -2.99% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Reiterated: Buy | $38 → $80 | $62.91 | +27.17% | 4 | Nov 7, 2025 |
Palvella Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $210
Current: $150.56
Upside: +39.48%
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $66.61
Upside: -
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $96.81
Upside: -
Theravance Biopharma
Mar 5, 2026
Downgraded: Hold
Price Target: $27 → $14
Current: $17.02
Upside: -19.68%
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $21.14
Upside: +65.56%
Ligand Pharmaceuticals
Nov 7, 2025
Reiterated: Buy
Price Target: $250 → $275
Current: $283.49
Upside: -2.99%
MBX Biosciences
Nov 7, 2025
Reiterated: Buy
Price Target: $38 → $80
Current: $62.91
Upside: +27.17%